Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 401-620-8 | CAS number: 87731-18-8 VIOLIFF
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- October 18, 1985 - November 13, 1985
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 986
- Report date:
- 1986
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- no
- GLP compliance:
- no
- Remarks:
- Study performed around/just before the time GLP was introduced in Europe, but internal QA statement.
- Test type:
- standard acute method
- Limit test:
- yes
Test material
- Reference substance name:
- Methoxycarbonyloxycyclooct-4-ene
- EC Number:
- 401-620-8
- EC Name:
- Methoxycarbonyloxycyclooct-4-ene
- Cas Number:
- 87731-18-8
- Molecular formula:
- C10H16O3
- IUPAC Name:
- (1R,3aS,6aS)-octahydropentalen-1-yl methyl carbonate; (1S,3aS,6aS)-octahydropentalen-1-yl methyl carbonate; (3Z)-cyclooct-3-en-1-yl methyl carbonate; (4Z)-cyclooct-4-en-1-yl methyl carbonate; bicyclo[3.2.1]octan-8-yl methyl carbonate
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: CD (Sprague-Dawley derived)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River U.K. Limited, Margate, Kent, UK
- Age at study initiation: 4 to 6 weeks
- Weight at study initiation: 100 to 151 g
- Fasting period before study: Overnight prior to and approximately 4 hours after dosing
- Housing: Group housed per sex in metal cages with wire mesh floors
- Diet: A standard laboratory rodent diet (Labsure LAD 1) was provided ad libitum
- Water: Water was provided ad libitum
- Acclimation period: minimum 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 - 22
- Humidity (%): 53 (daily mean)
- Air changes (per hr): approximately 15
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- MAXIMUM DOSE VOLUME APPLIED: 4.72 mL/kg (relative density 1.0593)
- Doses:
- Preliminary study: 1000, 2500 and 5000 mg/kg bodyweight
Main study: 2000, 2500, 3200, 4000 and 5000 mg/kg bodyweight - No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Animals were observed directly after dosing; then at frequent intervals for the remainder of Day 1. On subsequent days the animals were observed at least twice per day. Clinical signs were recorded at each observation.
- Necropsy of survivors performed: yes, all animals on the main study were killed on Day 15 by cervical dislocation and subjected to a macroscopic post mortem examination
- Body weights: Days 1, 8 and 15 and at death - Statistics:
- Finney (1971) Probit Analysis (3rd Edition) Cambridge University Press
Results and discussion
- Preliminary study:
- The LD50 was between 2500 and 5000 mg/kg bodyweight
Effect levelsopen allclose all
- Key result
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 4 200 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- > 3 400 - < 5 500
- Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 2 400 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- > 1 900 - < 2 900
- Mortality:
- Deaths occurred amongst male rats dosed at 4000 mg/kg and above (2 at 4000 and 5 at 5000 mg/kg) and amongst female rats dosed at 2000 g/kg and above (2 at 2000, 3 at 2500, 4 at 3200, 4 at 4000 and 5 at 5000 mg/kg) within 22 and 47 hours of dosing.
- Clinical signs:
- other: Signs of reaction to treatment observed shortly after dosing in all rats were pilo-erection, abnormal body carriage (hunched posture), abnormal gait (waddling), lethargy, decreased respiratory rate, pallor of the extremities and increased salivation. The
- Gross pathology:
- No abnormalities were observed in surviving animals. In animals that died during the study pallor of the liver, kidneys and spleen were seen.
Applicant's summary and conclusion
- Interpretation of results:
- other: Not harmful according to EU CLP (1272/2008 and its amendments)
- Conclusions:
- The substance has a female LD50 of 2400 mg/kg bw and a male LD50 of 4200 mg/kg bw.
- Executive summary:
The substance was tested in an acute oral toxicity study with male and female Sprague-Dawley rats (OECD TG 401). Based on the results of a preliminary study, the following doses were used in the main study: 2000, 2500, 3200, 4000 and 5000 mg/kg bw. Deaths occurred amongst male rats dosed at 4000 mg/kg and above and amongst female rats dosed at 2000 g/kg and above within 22 and 47 hours of dosing. Signs of reaction to treatment observed shortly after dosing in all rats were pilo-erection, abnormal body carriage (hunched posture), abnormal gait (waddling), lethargy, decreased respiratory rate, pallor of the extremities and increased salivation. These were accompanied by: ptosis in all male rats treated at 3200 mg/kg and in one male rat treated at 4000 mg/kg, a comatose-like condition amongst rats in all dose groups, increased lacrimation amongst rats dosed at 2500, 3200 and 4000 mg/kg. Recovery as judged by external appearance and behaviour was apparently complete by Day 5. Body weight losses were recorded for all but one of the rats that died and one surviving female at 2000 mg/kg. No abnormalities were observed in surviving animals. In animals that died during the study pallor of the liver, kidneys and spleen were seen. The female LD50 resulted in 24000 mg/kg bw (between 1900 and 2900 mg/kg bw) and the male LD50 resulted in 4200 mg/kg bw (between 3400 and 5500 mg/kg bw).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.